Mark R. Goldstein, MD; Luca Mascitelli, MD
Potential Conflicts of Interest: None disclosed.
Goldstein MR, Mascitelli L. An Update on the Comparative Effectiveness and Safety of Medications for Type 2 Diabetes. Ann Intern Med. 2011;155:562-563. doi: 10.7326/0003-4819-155-8-201110180-00020
Download citation file:
Published: Ann Intern Med. 2011;155(8):562-563.
TO THE EDITOR:
We concur with the recent article by Bennett and colleagues (1) that metformin should be the preferred first-line therapy for type 2 diabetes. However, important safety issues regarding dipeptidyl peptidase-4 (DPP-4) inhibitors have recently emerged (2), bolstering disturbing signals raised several years ago in premarket studies with these agents. It is therefore disconcerting that the American Association of Clinical Endocrinologists and the American College of Endocrinology recommend treatment with a DPP-4 inhibitor as an option for initial monotherapy of type 2 diabetes (1).
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only